Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Study on the Use of Envafolimab Combined With Suvemcitug and HAIC for the Conversion Therapy of Potentially Resectable Hepatocellular Carcinoma

NCT07738055 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.

NCT NCT07738055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07738055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Study on the Use of Envafolimab Combined With Suvemcitug and HAIC for the Conversion Therapy of Potentially Resectable Hepatocellular Carcinoma
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
July 31, 2029
Enrollment
35 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

potentially resectable hepatocellular carcinoma